Roy-Chowdhuri Sinchita
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Transl Lung Cancer Res. 2020 Jun;9(3):898-905. doi: 10.21037/tlcr.2019.12.31.
With a growing number of predictive biomarkers that have emerged in non-small cell lung carcinoma (NSCLC), there has been a paradigm shift in the management of these patients. Of the various predictive biomarker testing methods, immunohistochemistry (IHC) is the most widely available, cost-effective, and commonly used methods. However, most predictive IHC assays are validated primarily on formalin-fixed paraffin-embedded (FFPE) histologic tissue samples and translating these assays to cytologic specimens requires additional and rigorous validation. This is part due to the lack of standardized processing protocols in cytology resulting in a variety of preanalytic variables that can impact the antigenicity of antibodies used for predictive biomarker testing. The review article discusses the various preanalytical and analytical factors that impact immunocytochemistry (ICC) in cytologic specimens and summarizes the current published literature on , , PD-L1, and other predictive biomarker ICC in cytology.
随着非小细胞肺癌（NSCLC）中出现的预测性生物标志物越来越多，这些患者的管理模式发生了转变。在各种预测性生物标志物检测方法中，免疫组织化学（IHC）是应用最广泛、性价比最高且最常用的方法。然而，大多数预测性IHC检测主要在福尔马林固定石蜡包埋（FFPE）组织学组织样本上得到验证，将这些检测方法应用于细胞学标本需要额外且严格的验证。部分原因是细胞学缺乏标准化的处理方案，导致多种分析前变量会影响用于预测性生物标志物检测的抗体的抗原性。这篇综述文章讨论了影响细胞学标本免疫细胞化学（ICC）的各种分析前和分析因素，并总结了当前已发表的关于、、程序性死亡配体1（PD-L1）以及细胞学中其他预测性生物标志物ICC的文献。
